Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Chakun McDaniel

Nurse Practitioner Gastonia, NC Nurse Practitioner

NPI 1316416555 CMS profile 11008243

3050 Riverwood Pkwy Ste B, Gastonia, NC 28056

Open in the dashboard

General payments

$10,604

476 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chakun McDaniel of Gastonia, NC is reported in the CMS Open Payments database as having received $10,604 across 476 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,153 142
2024 General $1,853 76
2023 General $977 44
2022 General $2,456 105
2021 General $2,164 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chakun McDaniel
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Chakun McDaniel were reported at $3,153. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Chakun McDaniel Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $2,164 $135 $40–$426 $132
2022 $2,456 $152 $48–$470 $149
2023 $977 $166 $54–$529 $160
2024 $1,853 $173 $55–$556 $164
2025 $3,153 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,616 91 payments
  2. ITI, Inc. $1,409 48 payments
  3. Otsuka America Pharmaceutical, Inc. $1,266 52 payments
  4. Teva Pharmaceuticals USA, Inc. $1,054 25 payments
  5. Supernus Pharmaceuticals, Inc. $986 44 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $504 26 payments
  7. Vanda Pharmaceuticals Inc. $480 18 payments
  8. Neurocrine Biosciences, Inc. $472 30 payments
  9. E.R. Squibb & Sons, L.L.C. $377 19 payments
  10. Lundbeck LLC $363 19 payments
  11. Other $2,078 104 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,418 473 payments
  2. Education $186 3 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,111 68 payments
  2. CAPLYTA Psychiatry $1,081 38 payments
  3. REXULTI Psychiatry $1,062 46 payments
  4. Qelbree $724 25 payments
  5. Austedo XR $707 17 payments
  6. FANAPT $480 18 payments
  7. INGREZZA $472 30 payments
  8. COBENFY $354 18 payments
  9. CAPLYTA Psychiatry $328 10 payments
  10. REXULTI Psychiatry $294 15 payments
  11. Other $4,578 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 39 drugs

Part D claims

1,827

Median for Nurse Practitioner: 389

Drug cost

$181,224

Median for Nurse Practitioner: $21,885

Branded share of claims

19.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 45 $77,576
Fanapt Iloperidone Brand 12 $30,679
Rexulti Brexpiprazole Brand 15 $29,497
Lurasidone Hcl Generic 37 $8,564
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 35 $5,826
Vyvanse Lisdexamfetamine Dimesylate Brand 15 $5,817
Quetiapine Fumarate Generic 121 $2,932
Aripiprazole Generic 80 $2,449
Duloxetine Hcl Generic 72 $1,987
Bupropion Xl Bupropion Hcl Brand 111 $1,650

The 10 drugs with the highest cost, of 39 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $468
$468 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $319
$319 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $184
  • Lundbeck LLC $74
$258 15 —
CAPLYTA
  • ITI, Inc. $175
$175 — —
VRAYLAR
  • AbbVie, Inc. $143
$143 45 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

476 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record